» Articles » PMID: 28420073

Future Prospects for the Development of Cost-Effective Adenovirus Vaccines

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2017 Apr 20
PMID 28420073
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccination is one of the most efficient tools for disease prevention, and a continuously growing field of research. However, despite progress, we still need more efficient and cost-effective vaccines that would improve access to those in need. In this review, we will describe the status of virus-vectored vaccine technology with a focus on adenoviral-based vaccines. Adenovirus (Ad) vaccines have proven to be efficient in military vaccinations against Ad4 and Ad7 and as highly efficient vectored vaccines against rabies. The question of how other adenovirus-based vaccines can become as efficient as the rabies vaccine is the underlying theme in this review. Here, we will first give an overview of the basic properties of vectored vaccines, followed by an introduction to the characteristics of adenoviral vectors and previously tested modifications of the vector backbone and expression cassettes, with a focus on how they can contribute to increased vaccine cost-effectiveness. Finally, we will highlight a few successful examples of research that have attempted to improve the use of adenoviral-based vaccines by improving the transgene immunogenicity.

Citing Articles

Cancer vaccines: an update on recent achievements and prospects for cancer therapy.

Chekaoui A, Garofalo M, Gad B, Staniszewska M, Chiaro J, Pancer K Clin Exp Med. 2024; 25(1):24.

PMID: 39720956 PMC: 11669620. DOI: 10.1007/s10238-024-01541-7.


A Comprehensive Review of Our Understanding and Challenges of Viral Vaccines against Swine Pathogens.

Kamboj A, Dumka S, Saxena M, Singh Y, Kaur B, da Silva S Viruses. 2024; 16(6).

PMID: 38932126 PMC: 11209531. DOI: 10.3390/v16060833.


User-Friendly Replication-Competent MAdV-1 Vector System with a Cloning Capacity of 3.3 Kilobases.

Zhang Z, Guo X, Hou W, Zou X, Wang Y, Liu S Viruses. 2024; 16(5).

PMID: 38793642 PMC: 11126015. DOI: 10.3390/v16050761.


The Biodistribution of Replication-Defective Simian Adenovirus 1 Vector in a Mouse Model.

Chen J, Guo X, Zou X, Wang M, Yang C, Hou W Viruses. 2024; 16(4).

PMID: 38675893 PMC: 11054548. DOI: 10.3390/v16040550.


A Review of Clinical Trials of Cancer and Its Treatment as a Vaccine.

Chandarana C, Tiwari A Rev Recent Clin Trials. 2023; 19(1):7-33.

PMID: 37953617 DOI: 10.2174/0115748871260733231031081921.


References
1.
Mizuguchi Y, Takizawa T, Uchida E . Host cellular microRNA involvement in the control of hepatitis B virus gene expression and replication. World J Hepatol. 2015; 7(4):696-702. PMC: 4388997. DOI: 10.4254/wjh.v7.i4.696. View

2.
Karen K, Deal C, Adams R, Nielsen C, Ward C, Espinosa D . A replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys. Infect Immun. 2014; 83(1):268-75. PMC: 4288877. DOI: 10.1128/IAI.02626-14. View

3.
Choudhry A, Mathena J, Albano J, Yacovone M, Collins L . Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits. Vaccine. 2016; 34(38):4558-4564. DOI: 10.1016/j.vaccine.2016.07.033. View

4.
Lasaro M, Ertl H . New insights on adenovirus as vaccine vectors. Mol Ther. 2009; 17(8):1333-9. PMC: 2835230. DOI: 10.1038/mt.2009.130. View

5.
Ferreira T, Alves P, Aunins J, Carrondo M . Use of adenoviral vectors as veterinary vaccines. Gene Ther. 2005; 12 Suppl 1:S73-83. PMC: 7091679. DOI: 10.1038/sj.gt.3302618. View